SynthesisDrugs & aging2019
Clinical Outcomes Associated with Drug-Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review.
Synthesis in Drugs & aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- Assessing safety trends of withdrawn medications: A data-driven pharmacovigilance approach using growth models.Exploratory research in clinical and social pharmacy · 2026Article
- Pharmacokinetic Drug-Drug Interaction Potential of Oral Anticancer Drugs.Clinical pharmacology and therapeutics · 2026Article
- Assessment of potential drug interactions in rheumatology: a comparative study of decision support software.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Impact of Drug-Drug Interactions on Clinical Outcomes in Metastatic Melanoma Patients Treated With Combined BRAF/MEK Inhibitors: A Real-World Study.Pigment cell & melanoma research · 2025Observational
- Medication patterns and potentially inappropriate medication in patients with metastatic breast cancer: results of the BRE-BY-MED study.BMC cancer · 2025Article
- Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.NPJ breast cancer · 2024Article
- Article
- Managing Drug Interactions With Oral Anticancer Treatments.Journal of the advanced practitioner in oncology · 2023Article
- A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug-Drug Interaction Liabilities.Pharmaceutics · 2022Article
- Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers.JCO precision oncology · 2022Article
- Importance of medication reconciliation in cancer patients.Journal of pharmaceutical policy and practice · 2021Article
- Article
- Drug-Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PINPharmaceuticals (Basel, Switzerland) · 2021Article
- Improvement Initiative to Develop and Implement a Tool for Detecting Drug-Drug Interactions During Oncology Clinical Trial Enrollment Eligibility Screening.Journal of patient safety · 2021Article
- The potential roles of Nrf2/Keap1 signaling in anticancer drug interactions.Current research in pharmacology and drug discovery · 2021Review
- Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundOral chemotherapy use is increasing due to new drug approvals as well as the convenience of the administration of oral drugs. This increased use also raises concern regarding drug-drug interactions (DDIs) with concomitantly administered drugs, resulting in loss of therapeutic effect, decreased tolerability, and/or increased toxicity.
objectiveThe objective of this study was to review existing evidence of the clinical impact of DDIs with oral chemotherapeutic agents.
methodsA comprehensive search of literature using PubMed was conducted in April 2018 for studies of DDIs associated with oral chemotherapy. Included studies were in English. We included randomized clinical trials, observational studies, and case reports evaluating a DDI between any oral chemotherapy drug and any other drug. Included studies needed to have at least one outcome of clinical relevance potentially attributed to the DDI, for example, effects on survival or toxicity. The quality of the articles was determined using published metrics appropriate for the study design.
resultsThere were 2626 studies identified in the initial search, of which 35 met all eligibility criteria. These included 15 retrospective cohort studies, 16 case reports or case series and four post hoc analyses of clinical trials. Among these, DDIs contributed to a statistically significant change in a clinical outcome in 12 studies. Eight of these studies evaluated overall survival and progression-free survival and found that the presence of the DDI was associated with reduced survival.
conclusionOur findings suggest that more real-world studies evaluating the association between oral chemotherapy DDIs and clinical outcomes are needed. The adverse clinical outcomes due to DDIs may be a reason for treatment failures and therapy discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.